new_0222_0271|VERV|Short Name|0|0|total_current_assets|cash_on_hand|inventories_net|net_ppe|goodwill_and_intangible|liabilities|total_current_liabilities|total_long_term_liab|total_deposits|book_value_of_equity|retained_earnings|treasury_stock|ev_revenues|ev_earnings|ev_free_cash_flow|ev_assets|ps_ratio|pe_ratio|price_to_book_value|peg_ratio|debt_equity_ratio|dividend_yield|shareholder_yield_ttm|percent_of_shares_outstanding|receivables|payables|capital_stock|return_on_invested_capital|quality_ratio_fractile|momentum_fractile|market_beta_12_month|sustainable_growth_rate|institutional_investor_ownership_percentage|average_shares_outs_diluted|total_employee_number|eps|sga_expense|shares_outstanding|repurchase_of_capital_stock|ordinary_shares_number|payout_ratio|quick_ratio|normalized_eps|stock_buyback|effective_tax_rate|return_on_equity|net_income_ttm|revenues_ttm|dividend_per_share|revenues|gross_profit|pre_tax_income|net_income|interest_income|price|total_return_price|enterprise_value|average_volume_30|one_year_return|short_interest|forward_pe_ratio|forward_pe_ratio_1y|forward_ps_ratio|forward_ps_ratio_1y|quarterly_eps_estimates|quarterly_sales_estimates|quarterly_eps_surprise|quarterly_sales_surprise|quarterly_eps_actual|quarterly_sales_actual|sales_est_0y|sales_est_1y|price_target|consensus_recommendation|price_target_num_est|eps_est_0y|eps_est_1y|r_and_d_expense|reconciled_depreciation|interest_expense_non_operating|land_and_improvements|buildings_and_improvements|other_properties|machinery_furniture_equipment
new_0222_0271|VERV|Long Name|1|1|Verve Therapeutics Inc Total Current Assets (Quarterly) (USD)|Verve Therapeutics Inc Cash and Short Term Investments (Quarterly) (USD)|Verve Therapeutics Inc Inventories (Quarterly) (USD)|Verve Therapeutics Inc Net PP&E (Quarterly) (USD)|Verve Therapeutics Inc Goodwill and Intangibles (Quarterly) (USD)|Verve Therapeutics Inc Total Liabilities (Quarterly) (USD)|Verve Therapeutics Inc Total Current Liabilities (Quarterly) (USD)|Verve Therapeutics Inc Total Long Term Liabilities (Quarterly) (USD)|Verve Therapeutics Inc Total Deposits (Quarterly) (USD)|Verve Therapeutics Inc Book Value (Quarterly) (USD)|Verve Therapeutics Inc Retained Earnings (Quarterly) (USD)|Verve Therapeutics Inc Treasury Stock (Quarterly) (USD)|Verve Therapeutics Inc EV to Revenues|Verve Therapeutics Inc EV to Earnings|Verve Therapeutics Inc EV to Free Cash Flow|Verve Therapeutics Inc EV to Assets (Quarterly)|Verve Therapeutics Inc PS Ratio|Verve Therapeutics Inc PE Ratio|Verve Therapeutics Inc Price to Book Value|Verve Therapeutics Inc PEG Ratio|Verve Therapeutics Inc Debt to Equity Ratio|Verve Therapeutics Inc Dividend Yield|Verve Therapeutics Inc Shareholder Yield (TTM)|Verve Therapeutics Inc Percent of Shares Outstanding Short|Verve Therapeutics Inc Total Receivables (Quarterly) (USD)|Verve Therapeutics Inc Total Payables (Quarterly) (USD)|Verve Therapeutics Inc Total Capital Stock (Quarterly) (USD)|Verve Therapeutics Inc Return on Invested Capital|Verve Therapeutics Inc Quality Ratio Score|Verve Therapeutics Inc Momentum Score|Verve Therapeutics Inc Beta (1Y)|Verve Therapeutics Inc Sustainable Growth Rate (TTM)|Verve Therapeutics Inc Institutional Investor Ownership Percentage|Verve Therapeutics Inc Average Diluted Shares Outstanding (Quarterly)|Verve Therapeutics Inc Total Employees (Annual)|Verve Therapeutics Inc EPS Diluted (Quarterly) (USD)|Verve Therapeutics Inc SG&A Expense (Quarterly) (USD)|Verve Therapeutics Inc Shares Outstanding|Verve Therapeutics Inc Repurchase of Capital Stock (Quarterly) (USD)|Verve Therapeutics Inc Ordinary Shares Number (Quarterly)|Verve Therapeutics Inc Payout Ratio|Verve Therapeutics Inc Quick Ratio (Quarterly)|Verve Therapeutics Inc Normalized Diluted EPS (Quarterly) (USD)|Verve Therapeutics Inc Stock Buybacks (Quarterly) (USD)|Verve Therapeutics Inc Effective Tax Rate (TTM)|Verve Therapeutics Inc Return on Equity|Verve Therapeutics Inc Net Income (TTM) (USD)|Verve Therapeutics Inc Revenue (TTM) (USD)|Verve Therapeutics Inc Dividend Per Share (Quarterly) (USD)|Verve Therapeutics Inc Revenue (Quarterly) (USD)|Verve Therapeutics Inc Gross Profit (Quarterly) (USD)|Verve Therapeutics Inc Pre-Tax Income (Quarterly) (USD)|Verve Therapeutics Inc Net Income (Quarterly) (USD)|Verve Therapeutics Inc Net Interest Income (Quarterly) (USD)|Verve Therapeutics Inc Price (USD)|Verve Therapeutics Inc Total Return Price (USD)|Verve Therapeutics Inc Enterprise Value (USD)|Verve Therapeutics Inc 30-Day Average Daily Volume|Verve Therapeutics Inc 1 Year Price Returns (Daily)|Verve Therapeutics Inc Short Interest|Verve Therapeutics Inc PE Ratio (Forward)|Verve Therapeutics Inc PE Ratio (Forward 1y)|Verve Therapeutics Inc PS Ratio (Forward)|Verve Therapeutics Inc PS Ratio (Forward 1y)|Verve Therapeutics Inc Quarterly EPS Estimates (USD)|Verve Therapeutics Inc Quarterly Revenue Estimates (USD)|Verve Therapeutics Inc Quarterly EPS Surprise|Verve Therapeutics Inc Quarterly Revenue Surprise|Verve Therapeutics Inc Quarterly Actual EPS (USD)|Verve Therapeutics Inc Quarterly Actual Revenue (USD)|Verve Therapeutics Inc Revenue Estimates for Current Fiscal Year (USD)|Verve Therapeutics Inc Revenue Estimates for Next Fiscal Year (USD)|Verve Therapeutics Inc Price Target (USD)|Verve Therapeutics Inc Consensus Recommendation|Verve Therapeutics Inc Price Target Num Estimates|Verve Therapeutics Inc EPS Estimates for Current Fiscal Year (USD)|Verve Therapeutics Inc EPS Estimates for Next Fiscal Year (USD)|Verve Therapeutics Inc Research and Development Expense (Quarterly) (USD)|Verve Therapeutics Inc Reconciled Depreciation (Quarterly) (USD)|Verve Therapeutics Inc Non-Operating Interest Expense (Quarterly) (USD)|Verve Therapeutics Inc Land and Improvements (Quarterly) (USD)|Verve Therapeutics Inc Buildings and Improvements (Quarterly) (USD)|Verve Therapeutics Inc Other Properties (Quarterly) (USD)|Verve Therapeutics Inc Machine, Furniture & Equipment (Quarterly) (USD)
new_0222_0271|VERV|Unit|2|2|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|percent_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_beta|percent_USD_metric|percent_USD_metric|mil_figure_USD_metric|figure_whole_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_money_USD_price|mil_figure_money_USD_metric|figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_per_share_metric|percent_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_USD_metric|figure_whole_USD_price|figure_money_USD_per_share_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric
new_0222_0271|VERV||4|4|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|quarterly|quarterly|daily|quarterly|quarterly|daily|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|monthly|monthly|monthly|monthly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly
new_0222_0271|VERV||5|5|91|91|0|91|0|91|91|91|0|91|91|0|0|0|1.43859649123|0|0|0|1.43827160494|0|0|1.43859649123|0|15.3571428571|0|91|91|0|0|0|0|0|30.7142857143|91.3333333333|0|91.3333333333|91.3333333333|24.5|0|91|0|0|91.3333333333|91.4|0|0|91|0|0|0|0|91.3333333333|91.3333333333|91.3333333333|1.43859649123|1.43859649123|1.43859649123|1.43661971831|0|15.3571428571|0|0|0|0|91.5|91.5|92|0|92|92|18.4|20.375|23|11.5|23|15.3333333333|20.375|91.3333333333|91.3333333333|0|0|0|91|91
new_0222_0271|VERV||6|6|3|3|0|3|0|3|3|3|0|3|3|0|0|0|171|0|0|0|162|0|0|171|0|14|0|3|3|0|0|0|0|0|7|6|0|6|6|6|0|3|0|0|6|5|0|0|3|0|0|0|0|6|6|6|171|171|171|142|0|14|0|0|0|0|6|6|1|0|1|1|10|8|8|16|8|12|8|6|6|0|0|0|3|3
new_0222_0271|VERV||7|7|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|daily|quarterly|daily|daily|daily|daily|quarterly|daily|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|monthly|quarterly|yearly|quarterly|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|market_daily|market_daily|daily|market_daily|market_daily|daily|daily|daily|daily|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|daily|daily|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly
new_0222_0271|VERV|202003|202003|202003||||||||||||||||||||||||||||||||||29.1735||-0.1921|0.846||||||-0.1921|||||||||-5.603|-5.603|0.077||||||||||||||||||||||||6.523|0.165|||||
new_0222_0271|VERV|202006|202006|202006||||||||||||||||||||||||||||||||||29.1735||-0.2598|1.032||||||-0.2598|0||||||||-7.58|-7.58|0.05||||||||||||||||||||||||5.654|0.286|||||
new_0222_0271|VERV|202009|202009|202009||||||||||||||||||||||||||||||||||29.1735||-0.3082|1.354||||||-0.3082|0||||||||-8.99|-8.99|0.037||||||||||||||||||||||||7.618|0.624|||||
new_0222_0271|VERV|202012|202012|202012|73.966|72.112||3.984||142.322|7.315|135.007||-63.909|-66.536|||||||||||||||0.036|0.003|||||||29.1735||-0.8066|2.024|||43.8222|||-0.8066||||-45.704|||||-23.531|-23.531|-0.002||||||||||||||||||||||||15.576|0.253||||3.937|0.586
new_0222_0271|VERV|202103|202103|202103|151.841|149.523||5.202||234.6|6.684|227.916||-76.431|-79.799|||||||||||||||2.487|0.003|||||||29.1735|70|-0.45|2.716|||43.8222|||-0.45||||-53.364|||||-13.263|-13.263|0.02||||||||||||||||||||||||11.345|0.294||||5.34|0.629
new_0222_0271|VERV|202106|202106|202106|419.564|417.624||6.417||21.122|8.649|12.473||405.396|-132.764||||-45.6511||||7.1259|||0||2.3747||1.53|0.048||||||74.3532|7.9481||-6.66|3.541|47.947||47.947|||-6.66|-285.214|||-98.749|||||-52.965|-52.965|0.005|60.25|60.25|2471.1828|||1138586|||||-0.4897|0|-125.3763||-1.1036|0||||||||13.423|0.357||||6.754|0.68
new_0222_0271|VERV|202107|202106|202106|||||||||||||||-44.9247||||7.0289|||0||3.805|||||||||74.6234||||||||||||||||||||||59.43|59.43|2431.8662|534456.4333||1824382|||||||||||0|0|68.6667|1.5|3|-3.2692|-2.3897|||||||
new_0222_0271|VERV|202108|202106|202106|||||||||||||||-54.3095||||8.282|||0||3.8762|||||||||74.3513|||||47.9918|||||||||||||||||69.96|69.96|2939.8823|294056.4667||1860245|||||||||||0|0|69.6667|1.5|3|-6.9033|-2.4722|||||||
new_0222_0271|VERV|202109|202109|202109|394.437|389.21||8.909||25.942|20.251|5.691||384.935|-155.513||||-27.0543||||5.8707|||0||4.6247||3.579|0.048||||||77.1183|47.9928||-0.47|6.007|48.0814||48.0814|||-0.47|0|||-112.508|||||-22.749|-22.749|0.053|47|47|1870.6158|472168.2333||2223623|||||-0.4454|0|-5.535||-0.47|0|0|0|66.75|1.8|4|-5.9575|-2.4877|17.495|0.412||||9.793|0.711
new_0222_0271|VERV|202110|202109|202109|||||||||||||||-26.6301||||5.7945|||0||6.9057|||||||||77.6724||||||||||||||||||||||46.39|46.39|1841.2861|325901.2667||3320336|||||||||||0|0|61|2|3|-3.63|-2.4971|||||||
new_0222_0271|VERV|202111|202109|202109|||||||||||||||-18.114||||4.2648|||0||9.6636|||||||||78.1316|||||48.171|||||||||||||||||34.08|34.08|1252.4577|290255.2333||4655062|||||||||||0|0|66.75|1.8|4|-5.57|-2.524|||||||
new_0222_0271|VERV|202112|202112|202112|||||||||||||||-20.0578||||4.6139|||0||12.7407|||||||||83.8254||||||||||||||||||||||36.87|36.87|1386.8548|617459||6137303|||||-0.5583|0|||||0|0|70.4|1.6667|5|-5.0317|-2.3667|||||||
new_0222_0271|VERV|202201|202112|202112|||||||||||||||-14.4494||||3.6066|||0||14.3046|||||||||83.2679||||||||||||||||||||||28.82|28.82|999.0782|759616.2333||6890661|||||||||||0||70.4|1.6667|5|-2.3667||||||||
new_0222_0271|VERV|202202|202112|202112|||||||||||||||-13.0143||||3.3488|||0|||||||||||||||||||||||||||||||||26.76|26.76|899.846|619736.8667||||||||||||||||||||||||||
new_0222_0271|VERV|202203|202203|202203|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-0.5575|0||||||||||||||||||
new_0222_0271|VERV|202206|202206|202206|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-0.5725|0||||||||||||||||||
new_0222_0271|VERV|202209|202209|202209|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-0.5875|0||||||||||||||||||
new_0222_0271|VERV|202212|202212|202212|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-0.5975|0||||||||||||||||||